Marksans Pharma Ltd
MARKSANS
Company Profile
Business description
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Contact
Veera Desai Extension Road
11th Floor, Grandeur
Opposite Gundecha Symphony
Oshiwara, Andheri (West)
MumbaiMH400053
INDT: +91 2240012000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
2,657
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,194.90 | 12.40 | -0.13% |
| CAC 40 | 8,112.02 | 146.92 | -1.78% |
| DAX 40 | 24,959.06 | 338.07 | -1.34% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,195.35 | 39.94 | -0.39% |
| HKSE | 26,563.90 | 281.06 | -1.05% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,583.57 | 352.60 | -0.65% |
| NZX 50 Index | 13,580.29 | 137.81 | -1.00% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,874.50 | 9.20 | -0.10% |
| SSE Composite Index | 4,114.00 | 12.09 | 0.29% |